Zentalis Pharmaceuticals (ZNTL) Non-Current Deferred Tax Liability (2019 - 2023)

Zentalis Pharmaceuticals has reported Non-Current Deferred Tax Liability for 5 years, with the latest figure at $10.3 million in Q4 2023.

• For the quarter ending Q4 2023, Non-Current Deferred Tax Liability rose 1112.08% year-over-year to $10.3 million; the trailing twelve-month figure through Dec 2023 stood at $10.3 million (up 1112.08% YoY), and the FY2023 full-year result was $10.3 million, up 1112.08% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2023 stood at $10.3 million, up from $756000.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $10.3 million in Q4 2023, with the low at $756000.0 in Q1 2023.
• Average Non-Current Deferred Tax Liability over 5 years is $2.5 million, with a median of $2.5 million recorded in 2020.
• Peak annual rise in Non-Current Deferred Tax Liability reached 1112.08% in 2023, while the deepest fall reached 51.16% in 2023.
• Tracing ZNTL's Non-Current Deferred Tax Liability over 5 years: stood at $3.2 million in 2019, then fell by 22.84% to $2.5 million in 2020, then slumped by 34.6% to $1.6 million in 2021, then sank by 47.41% to $853000.0 in 2022, then soared by 1112.08% to $10.3 million in 2023.
• The last three Non-Current Deferred Tax Liability figures came in at $10.3 million (Q4 2023), $756000.0 (Q1 2023), and $853000.0 (Q4 2022), per Business Quant data.

Peer Comparison